1. Home
  2. AIRI vs LSTA Comparison

AIRI vs LSTA Comparison

Compare AIRI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

HOLD

Current Price

$3.21

Market Cap

16.9M

Sector

Industrials

ML Signal

HOLD

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$5.03

Market Cap

16.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRI
LSTA
Founded
1979
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Misc Health and Biotechnology Services
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9M
16.4M
IPO Year
2013
2000

Fundamental Metrics

Financial Performance
Metric
AIRI
LSTA
Price
$3.21
$5.03
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
146.5K
59.2K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
36.92
20.42
EPS
N/A
N/A
Revenue
$55,108,000.00
$35,283,868.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.97
56.90
52 Week Low
$2.55
$1.81
52 Week High
$4.17
$5.07

Technical Indicators

Market Signals
Indicator
AIRI
LSTA
Relative Strength Index (RSI) 47.69 71.48
Support Level $3.18 $2.31
Resistance Level $3.38 N/A
Average True Range (ATR) 0.15 0.08
MACD -0.01 0.03
Stochastic Oscillator 21.03 96.15

Price Performance

Historical Comparison
AIRI
LSTA

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: